Table 1

Comparison of baseline characteristics of two cohortsa
Characteristics Before After P-value
Patients, n 702 214
Observation period (person-years) 972.9 101.4
Females, n (%) 578 (82.3) 174 (81.3) 0.851
Age (years) 58.0 ± 14.3 58.9 ± 15.5 0.642
RA duration (months) 112 ± 125 92.9 ± 119 0.037
DAS28 score (ESR) 5.83 ± 1.24 5.45 ± 1.27 0.001
Coexisting pulmonary disease (%) 37.7 65.8 0.001
Diabetes mellitus (%) 12.7 9.80 0.268
Glucocorticoids (%)b 43.2 22.9 0.001
Methotrexate (%)c 78.5 87.9 0.002
Dose of methotrexate (mg/wk) 8.96 ± 2.46 9.51 ± 2.51 0.007
Serum level of IgG (mg/dl) 1590 ± 522 1600 ± 876 0.131
Serum level of KL-6 (U/ml) 271 ± 147 250 ± 194 0.086

aDAS28: Disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation rate; IgG: Immunoglobulin G. bThe use of glucocorticoids data are the percentage of patients treated with glucocorticoids. cThe use of methotrexate data are the percentage of patients treated with methotrexate. Compared with the group of 702 patients, the duration of RA was shorter and DAS28 score (ESR), the complication of pulmonary disease, and the use and dose of glucocorticoids were lower in 214 patients. The dose of methotrexate was increased after the adoption of the prophylaxis criterion. Data are mean ± SD by Wilcoxon rank-sum test.

Katsuyama et al.

Katsuyama et al. Arthritis Research & Therapy 2014 16:R43   doi:10.1186/ar4472

Open Data